Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01889667 · ClinicalTrials.gov registry record · Phase 2

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

A Phase 2 study, sponsored by Oramed.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT01889667 is a Phase 2 study that has completed, run by Oramed. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01889667, a Phase 2 study, has completed, sponsored by Oramed.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

The purpose of this study is to test the safety and pharmacodynamics of an oral formulation of insulin in subjects with Type 2 Diabetes.

Interventions

  • DRUG Placebo
  • DRUG ORMD-0801 Dose # 1
  • DRUG ORMD-0801 Dose # 2

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-06
Est. Completion 2013-11
Phase Phase 2

Sponsor

Oramed

11 total trials

What the Registry Record Tells You About NCT01889667

The ClinicalTrials.gov registry entry for NCT01889667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oramed, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01889667 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01889667 about?

NCT01889667 is a clinical study titled "Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)". The purpose of this study is to test the safety and pharmacodynamics of an oral formulation of insulin in subjects with Type 2 Diabetes.

What is the current status of trial NCT01889667?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-06. Estimated completion is 2013-11.

What interventions are being tested in trial NCT01889667?

The interventions under investigation include: Placebo (DRUG), ORMD-0801 Dose # 1 (DRUG), ORMD-0801 Dose # 2 (DRUG).

Who is sponsoring clinical trial NCT01889667?

This trial is sponsored by Oramed, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.